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Summary
Radiotherapy is an effective treatment modality for breast cancer but, unfortunately, not all patients respond fully with a
significant number experiencing local recurrences. Overexpression of thioredoxin and thioredoxin reductase has been reported
to cause multidrug and radiation resistance - their inhibition may therefore improve therapeutic efficacy. Novel indolequinone
compounds have been shown, in pancreatic cancer models, to inhibit thioredoxin reductase activity and exhibit potent anticancer
activity. The present study evaluates, using in vitro breast cancer models, the efficacy of a novel indolequinone compound (IQ9)
as a single agent and in combination with ionising radiation using a variety of endpoint assays including cell proliferation,
clonogenic survival, enzyme activity, and western blotting. Three triple-negative breast cancer (MDA-MB-231, MDA-MB-468,
andMDA-MB-436) and two luminal (MCF-7 and T47D) breast cancer cell lines were used. Results show that treatment with IQ9
significantly inhibited thioredoxin reductase activity, and inhibited cell growth and colony formation of breast cancer cells with
IC50 values in the low micromolar ranges. Enhanced radiosensitivity of triple-negative breast cancer cells was observed, with
sensitiser enhancement ratios of 1.20–1.43, but with no evident radiosensitisation of luminal breast cancer cell lines. IQ9
upregulated protein expression of thioredoxin reductase in luminal but not in triple-negative breast cancer cells which may
explain the observed differential radiosensitisation. This study provides important evidence of the roles of the thioredoxin system
as an exploitable radiobiological target in breast cancer cells and highlights the potential therapeutic value of indolequinones as
radiosensitisers.
***This study was not part of a clinical trial. Clinical trial registration number: N/A
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Background
Breast cancer is the most common form of cancer among
women with an estimated 2 million new cases diagnosed
across 185 countries in 2018 [1]. In the UK, an estimated
55,439 new cases and 11,849 deaths occurred from breast
cancer in 2018 [1]. Treatment is often effective; however,
according to the recent 2018 report by the Early Breast
Cancer Trialists’ Collaborative Group, a significant propor-
tion of early-stage breast cancer patients develop local recur-
rence (15.9% at 15 years) following adjuvant chemotherapy
[2]. Radiotherapy is an important treatment option in the man-
agement of breast cancer [3], playing a key role in early-stage
invasive, locally advanced, and metastatic breast cancers, ei-
ther as curative or palliative treatments [3]. Although an ef-
fective cancer treatment modality, radioresistance may result
in treatment failure [4]. There is a need to identify new agents
that can be combined in a rational way, to make radiotherapy
more effective. Cancer cells exist in conditions that result in
elevated levels of reactive oxygen species (ROS) and, as a
result, often develop highly effective antioxidant systems,
with expression and/or function at higher levels than normal
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cells which may, in turn, promote tumour formation and pro-
gression [5]. A modest increase in ROS levels can speed up
the rate of cancer cell proliferation by activating various sig-
nalling cascades linked to carcinogenesis such as the mitogen-
activated protein kinase pathway. However, a further increase
in ROS to a toxic level can activate ROS-induced cell death
pathways including apoptosis, necrosis, and autophagy [6].
The upregulation of antioxidant systems may also protect can-
cer cells from the cytotoxic effect of certain therapies that rely
upon induction of oxidative stress as a mechanism of action,
both chemotherapeutic agents and ionising radiation.
Therefore, modulating redox balance represent a potential
strategy for cancer therapy.
The thioredoxin (Trx) system is an important antioxidant
system involved in the maintenance of intracellular redox ho-
meostasis and the radioresponse of cancer cells [7]. It is com-
prised of Trx, thioredoxin reductase (TrxR), NADPH, and the
endogenous inhibitor of Trx; Trx-interacting protein (Txnip).
TrxR plays a critical role in the oxidative stress process. It
catalyses the reduction of oxidised Trx to its reduced and
biologically active, state in the presence of NADPH [8].
Reduced Trx interacts with a number of biomolecules, reduc-
ing them in turn, including peroxiredoxins which are respon-
sible for scavenging peroxides and protecting cells from an
oxidative environment [9]. In cancer cells, Trx may exhibit
different roles depending on the stage of cancer progression
[10]. At the early stage of tumorigenesis, increased levels of
Trx may assist in tumour development owing to its anti-
apoptotic capabilities, however, as the cancer progress into a
more advanced stage, Trx may promote cancer cell metastasis
and angiogenesis [10–12]. Tumour cells often have high
levels of Trx and TrxR than normal cells to cope with in-
creased ROS demand and therefore are more vulnerable to
inhibition of Trx/TrxR [13]. Previous studies have shown that
the inhibition of TrxR activity elevates the formation of ROS
which subsequently increases cancer cell sensitivity to irradi-
ation [14, 15]. There is a growing interest in developing small
molecule inhibitors of the Trx system, either as a single agent
or used as adjuncts to existing anticancer agents. Many of
these agents, however, have varying potency and target other
thiols [13]. Hence, it is important to develop specific inhibitors
that can only inhibit Trx or TrxR and not other enzymes.
Novel indolequinone derivatives (IQs), developed at the
University of Nottingham, United Kingdom, have been previ-
ously reported as potent inhibitors of TrxR activity in pancreatic
cancer cells and cell-free systems [16, 17], exhibiting potent
anticancer activity in both in vitro and in vivo models [16, 17].
The activation of indolequinone agents requires two-electron re-
duction catalysis by reductases, loss of the leaving group, and the
formation of iminium electrophiles that can alkylate TrxR at the
C-terminal selenocysteine site. The covalent binding of quinone
electrophiles to TrxR results in the irreversible inhibition of its
activity [16]. The aims of the current study were to evaluate the
potential therapeutic efficacy of one such indolequinone deriva-
tive, IQ9 (Fig. 1), as a single agent and in combination with
radiation in breast cancer models. IQ9 was chosen as, based on
structure-activity relationship (SAR) analysis, it is amongst the
most potent of the IQs [17].
Materials and methods
Cell lines
Five human breast cancer cell lines were used, representing
different breast cancer phenotypes: MDA-MB-231 and
MDA-MB-468 cells (both triple-negative breast cancer phe-
notype (TNBC) with wild type BRCA-1) were maintained in
minimal essential medium EAGLE (Sigma, UK) supplement-
ed with 10% iron supplemented donor bovine serum (DBS)
(Gibco, UK), 2 mM L-glutamine (Sigma, UK) and 1% peni-
cillin /streptomycin (Sigma, UK). MDA-MB-436 cells
(TNBC phenotype, with mutated BRCA-1) were maintained
in Dulbecco’s Modified Eagle Medium/ Nutrient Mixture F-
12 (Sigma, UK) supplemented with 10% iron supplemented
DBS and 1% penicillin /streptomycin. MCF-7 and T47D
(both luminal phenotypes) were maintained in RPMI1640
(Sigma, UK) supplemented with 10% iron supplemented
DBS and 1% penicillin /streptomycin. All cell lines were orig-
inally obtained from the American Type Culture Collection
and were cultured at 37 °C in a humidified incubator with 5%
CO2. Cell lines were used within a 15-passage window. All
cells were mycoplasma free and cancer cell line authentication
was verified by short tandem repeat DNA profiling every 4–
6 months (Promega Powerplex).
Preparation of IQ9
IQ9 was synthesised at the School of Chemistry, University of
Nottingham, United Kingdom by Professor Christopher
Moody and Dr. Martyn Inman according to methods previ-
ously reported [16]. The purity of IQ9 was >95%.
Thioredoxin reductase activity assay (insulin
reduction)
TrxR enzyme activity was assessed using an insulin reduction
assay [18]. Briefly, 2 × 106 cells were seeded, in triplicate, in
75c m2 tissue culture flasks. After 24 h, sub-confluent cells
were treated with either IQ9 (0–1000 nM) or 1000 nM
auranofin (as a positive control) for 4 or 48 h, then trypsinised,
washed, and resuspended in M-PER™ Mammalian Protein
Extraction Reagent (ThermoFisher, USA) supplemented with
1X Halt protease inhibitor and EDTA. Protein concentration
was determined using the Bradford assay. 80 μg of protein
lysates isolated from each treatment conditions and reaction
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mix (HE buffer (100 mM HEPES pH 7.2, 5 mM EDTA),
20 μM Trx, 1.7 mM insulin, 10 mM β-NADPH) were added
to the 96-well plate and incubated for 1 h at 37 °C. The reac-
tion was stopped by adding stop buffer containing 6 M gua-
nidine hydrochloride, 50 mM Tris, and 10 mM DTNB
(Sigma, UK), with a final pH of 8.0. The plate was read at
room temperature using a BMG Fluostar Optima Microplate
Reader at 412 nM wavelength. The TrxR activity was
expressed as the percentage of control, no drug-treated.
Cell proliferation assay
1 × 105 cells (2 × 105 for T47D’s) were seeded, in triplicate, in
6-well plates and incubated overnight before being treated
with IQ9 (0–5000 nM) or doxorubicin (400–600 nM) (posi-
tive control and comparator). Total cells were counted after
48 h using a haemocytometer. The total cell count in drug
treatment wells was normalised as a percentage of the total
cells in vehicle control wells.
Clonogenic survival assay
5 × 105 cells were seeded in T25 cm2 tissue culture flasks and
incubated overnight. The sub-confluent cells were then treated
either for 4-h or 48-h with IQ9 (0–5000 nM) or doxorubicin
(10–20 nM). Following drug treatment, cells were collected,
counted, and plated at low-density, in triplicate, and incubat-
ed, at 37 °C, 5% CO2, undisturbed, for 2 weeks for TNBC
cells and 3 weeks for luminal cells, for colony formation.
Colonies were fixed (50% methanol in 0.9% saline solution)
and stained (0.5% crystal violet solution). Colonies consisting
of more than 50 cells were confirmed by microscopy and
scored as survivors. The plating efficiency (PE) was calculat-
ed as numbers of colonies formed/ numbers of cells plated.
For single-agent treatment, drug or radiation, the surviving
fraction was calculated as: number of colonies formed/ (num-
bers of cell plated x PE). For drug radiation combination ex-
periments, cytotoxicity of drug treatment was accounted for
by calculating surviving fraction as: number of colonies
formed from each radiation dose/ (number of cells plated ×
PE × surviving fraction of drug-treated cell at 0 Gy).
Cell irradiation
Sub-confluent cells were irradiated with a dose of 2, 4, 6, or
8 Gy (at a dose rate of 0.87 Gy/min) using an RS225 x-ray
cabinet irradiation system (Xstrahl Limited, UK), fitted with a
0.5 mm Cu filter and run at 195 kV, 10 mA. Following irra-
diation, cells were immediately trypsinised and plated for
clonogenic survival. Sham-irradiated cells were used as con-
trols. Dose-response curves were plotted as a function of ra-
diation dose on a log/ linear plot. Clonogenic survival calcu-
lation software (CS-CAL), developed by the Translational
Radiation Oncology Group, German Cancer Research
Centre was used to fit survival curves to the linear-quadratic
(LQ) model (equation: S ¼ exp − αDþβD2ð Þb c ). The software
can be accessed online at http://angiogenesis.dkfz.de/
oncoexpress/software/cs-cal/. For drug-radiation combina-
tions, cells were treated with 1000 nM IQ9 (2500 nM for
T47D) for 4 h followed by irradiation (0–8 Gy). For 48 h drug
treatment experiments, MDA-MB-231 and T47D cells were
treated with clonogenic IC50 concentrations of IQ9 before
irradiation. The sensitiser enhancement ratio (SER), calculat-
ed by dividing the X-ray dose causing 1% cell survival in the
absence of drug treatment by the X-ray dose leading to 1% cell
survival in the presence of drug treatment, was used to evalu-
ate the degree of radiosensitisation.
Western blotting
Cells were treated with IQ9 (clonogenic IC50 concentrations)
for 48 h, harvested, and resuspended in 1 mL of RIPA buffer
(Sigma, UK) supplemented with 1X Halt phosphatase inhib-
itor cocktail, protease inhibitor cocktail, and EDTA. Samples
were run on an SDS-polyacrylamide gel and transferred onto a
0.2 μm nitrocellulose membrane (GE Healthcare). The mem-
brane was then blocked using 5% milk powder in 0.1% PBS/
Tween20, for 1 h at room temperature and then incubated with
primary antibody overnight at 4 °C. Anti-β-actin antibody
(Abcam) was used as a loading control. Primary antibodies
were rabbit anti-human Trx (Abcam; 1:1000), mouse anti-
human antibody (Abcam; 1:500), and rabbit anti-human
Txnip (Abcam; 1:500). For Trx and Txnip, bands were detect-
ed using an Odyssey FC Imager (LI-COR). Images were ob-
tained and fluorescence intensity quantified using Image
Studio Software (version 4). The signals for Trx and Txnip
were normalised against β-actin. For TrxR, bands were de-
tected using an Amersham Enhanced Chemiluminescence
system (GE Healthcare).
Statistical analysis
IC50 values were calculated from dose-response curves using
an SPSS regression model between inhibition ratios and con-
centration gradients. The radiobiological parameters: alpha
(α), beta (β), α/β ratio, and surviving fraction at 2 Gy (SF2)
were extracted from the survival curves fitted using the LQ
model. All results are presented as average ± standard devia-
tion (SD) of three independent experiments, each performed
in triplicate. Data were analysed using the student T-test and
ANOVA one-way test. Statistical analysis was performed




IQ9 is an effective inhibitor of TrxR
IQ9 effectively inhibits TrxR activity more after 4-h than 48-h
drug treatment, with inhibition being comparable to auranofin,
and being more effective in TNBC than luminal cell lines
(Fig. 1). Treatment with auranofin for 4 h, as the positive
control, resulted in an approximately 70–100% decrease in
TrxR activity across all cell lines. IQ9 at 1000 nM caused
complete inhibition of TrxR activity in all TNBC cell lines
however, in luminal cell lines approximately 70% inhibition
was obtained. Treatment with auranofin for 48 h significantly
inhibited approximately 80% TrxR activity in MDA-MB-231
(P < 0.001), however, in T47D cells, there was only 10% in-
hibition of TrxR activity compared to control. When the ex-
posure time to IQ9 was increased to 48 h, a significant inhi-
bition in TrxR activity was also observed in MDA-MB-231
cells, with no significant inhibition observed in T47D cells
(Table 1).
IQ9 suppresses cell proliferation and inhibits colony
formation of breast cancer cells
The cytotoxic effect of IQ9 was assessed by proliferation and
clonogenic survival assays with doxorubicin being used as a
positive control and drug comparator in each case. Cells be-
haved as expected, from the published literature, following
doxorubicin treatment (400–600 nM), giving 50–70% de-
crease in cell number across all cell lines [19, 20]. In terms
of antiproliferative effects, IQ9 behaved comparably to doxo-
rubicin with only T47D’s being significantly more responsive
to doxorubicin. Treatment with IQ9 for 48 h decreased breast
cancer cell growth in a dose-dependent manner (Fig. 1) with a
90% decrease in cell number observed at the highest
Fig. 1 The inhibition properties of IQ9. a Chemical structure of IQ9. b,c
TrxR activity after 4- or 48-h IQ9 treatment in breast cancer cell lines.
Auranofin (1000 nM) was used as a positive control. Data represent the
average TrxR activity ± SD of three independent experiments, with each
experiment conducted in duplicate. d Effect of IQ9 on cell proliferation
on breast cancer cells. Cells were treated with various concentrations of
IQ9 (0–5000 nM) for 48 h. Doxorubicin was used as a positive control
(400–600 nM). The average percentage of cell number (normalised to
original seeding density) was plotted against IQ9 concentration. Data
represent the average percentage cell number ± SD of three independent
experiments, with each experiment performed in triplicate. *P < 0.05 vs
control
Table 1 IC50 values for TrxR activity inhibition by IQ9
Cell lines IC50 (nM)
4 h 48 h
MDA-MB-231 272.0 ± 144.6 759.2±216.5
MDA-MB-468 439.5 ± 168.0 NA
MDA-MB-436 284.3 ± 169.8 NA
T47D 640.0 ± 250.4 1257.0±660.0
MCF-7 619.0 ± 247.1 NA
Data represent the average ± SD of three independent experiments, with
each experiment conducted in duplicate. Abbreviations: NA Not
applicable
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concentration used (1000 nM) across all cell lines. A dose-
dependent decrease in clonogenic survival was also observed,
at both 4- and 48-h drug treatments (Fig. 2) however, in this
instance doxorubicin was substantially more potent. The 48-h
proliferation IC50s were, for IQ9, lower than the clonogenic
IC50 across all cell lines (Table 2).
IQ9 sensitises breast cancer cells to radiation
following 4-h drug treatment
As can be seen from Fig. 3, all TNBC cell lines showed a
similar response to irradiation with SF2 values ranging from
0.19 to 0.36 and α/β ratio ranging from 10.28 to 30.03. The
two luminal cell lines were slightly more resistant to irradia-
tion with SF2 values from 0.38 to 0.47 and α/β ratio from
8.16 to 10.25. The radioresponse of the five breast cancer cell
lines used in the current study was as expected and compara-
ble to SF2 values in the literature [21, 22]. Treatment with IQ9
for 4 h significantly increased the radiosensitivity of MDA-
MB-231, MDA-MB-468, and MDA-MB-436 cells to irradia-
tion at 2, 4, 6, and 8 Gy (P < 0.05 for all doses) with SER
values of 1.20, 1.30, and 1.43, respectively (radiobiological
parameters are shown in Table 3). In MCF-7 cells, a signifi-
cant increase in radiosensitivity was only observed above
6 Gy irradiation (SER value 1.08), however, no altered
radiosensitisation was observed in T47D cells. When the drug
exposure time was increased to 48 h, no significant increase in
radiosensitivity was observed with either MDA-MB-231 or
T47D cells (Fig. 3). Table 3 summarises the SERs, α, β, α/
β ratio and SF2 values for all breast cancer cells.
IQ9 differentially regulates the expression of Trx
family proteins in breast cancer cells
The effect of IQ9 on the expression of Trx system proteins
(Trx, TrxR, and Txnip) was assessed across the five breast
cancer cell lines by Western blotting (Fig. 4). T47D cells
expressed the highest levels of Trx and Txnip compared with
the other four cell lines. The endogenous expression level of
TrxR was lower in MCF-7 than in MDA-MB-231, MDA-
MB-468, MDA-MB-436 and T47D cells. IQ9 increased ex-
pression of Trx in MDA-MB-231 (P = 0.003) but had no ef-
fect on the other four cell lines. Increased expression of TrxR
was seen in luminal cells following drug exposure but with
little effect, if any, in TNBC cells. Txnip expression was not
affected by IQ9 treatment in any of the breast cancer cell lines,
with no pattern evident between phenotypes.
Discussion
Deregulation of the Trx system has been observed in various
diseases including cancer [23], stroke [24], and cardiovascular
diseases [25]. Overexpression of TrxR protein has been re-
ported in many solid tumours, leading to increased TrxR ac-
tivity that may contribute to tumour development through its
growth-promoting capacities [10]. Previous data have shown
Fig. 2 Effect of IQ9 on clonogenic survival of breast cancer cells. Cells
were treated with various concentrations of IQ9 (0–5000 nM) for 4 or
48 h (a, b). Doxorubicin was used as a positive control (10–600 nM). The
cell survival curve is presented by plotted the surviving fraction against
various concentrations of IQ9. PEs were 48.0 ± 4.4% (MDA-MB-231),
46.3 ± 3.2% (MDA-MB-468), 12.3 ± 4.5% (MDA-MB-436), 15.0 ±
5.0% (T47D) and 26.7 ± 12.2% (MCF-7). Data represent the average
surviving fraction ± SD of three independent experiments, with each
experiment performed in triplicate
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increased antioxidant abilities may make cancer cells less re-
sponsive to treatments that rely upon the generation of oxida-
tive stress as their mechanism of action, such as radiotherapy
[26, 27]. Anticancer drugs such as cisplatin [28] and
motexafin gadolinium [29] have been reported to be TrxR
inhibitors, suggesting that targeting TrxR may, therefore, be
a useful therapeutic strategy both as a single modality and also
to combine with radiotherapy.
Previous studies have shown that IQ derivatives are potent
inhibitors of TrxR, however, no studies have been previously
conducted to assess the cytotoxicity or radiosensitising effects
of these agents in breast cancer models. Current TrxR enzyme
activity data show that IQ9, at 4-h drug treatment, is more
efficient in all TNBC than luminal breast cancer models.
Also, IQ9 more effectively inhibits TrxR enzyme activity in
MDA-MB-231 and T47D cells after 4-h than 48-h IQ9 treat-
ment. Such findings support previous findings of TrxR being
a target of indolequinones derivatives [16]. IQ9 gave compa-
rable effects to auranofin, the positive control, and compara-
tor. Auranofin is a well-characterised TrxR inhibitor and has
entered phase I/II clinical trials against lymphoma
(NCT01419691) and lung (NCT01737502) cancer.
The inhibition of TrxR activity has been shown to de-
crease cell proliferation and cell survival of cancer cells
[30]. In the current study, IQ9 demonstrated a potent an-
ticancer effect with the ability to inhibit cell growth and
colony formation of all five breast cancer cells. When
compared against the positive control drug, doxorubicin
was more po ten t than IQ9 when measured by
clonogenicity. The mechanism of action by which doxo-
rubicin acts upon cancer cells is via intercalation between
DNA base pairs on double helix and disruption of
topoisomerase-II-mediated DNA repair [31]. Any distur-
bance in DNA damage pathways may lead to significant
loss of clonogenic survival of cancer cells [32]. In com-
parison to other TrxR inhibitors, IQ9 appears to be more
potent against breast cancer cells with IC50 ranges from
0.2 to 2 μM compared to auranofin [33] (IC50 between 2
and 10 μM) [33]. Data suggest that IQ9 is a potentially
effective anticancer candidate for breast cancer. The cyto-
toxic effect of IQ9 on breast cancer cells may be linked
with the inhibition of TrxR activity. A previous study
reported that indolequinone derivatives were effective at
inhibiting TrxR activity and cell growth of pancreatic can-
cer cell lines with IC50’s in the low nanomolar range [16].
The current study also demonstrates that IQ9 inhibits
Table 2 Proliferation and clonogenic survival IC50 values
Cell lines IC50 (nM)
Cell proliferation Clonogenic survival
48 h 4 h 48 h
MDA-MB-231 246.5 ± 55.3 565.0 ± 29.5 324.3 ± 20.1
MDA-MB-468 425.3 ± 154.7 501.6 ± 170.7 916.1 ± 173.1
MDA-MB-436 171.3 ± 81.4 194.6 ± 4.5 235.8 ± 71.5
T47D 1432.3 ± 254.8 2072.0 ± 53.7 1880.0 ± 297.7
MCF-7 378.7 ± 42.4 340.5 ± 2.1 600.9 ± 113.6
Data represent the average ± SD of three independent experiments, with
each experiment performed in triplicate
Fig. 3 Effect of IQ9 on radiosensitivity of breast cancer cells after 4- and
48-h treatments (a, b). The radiation survival curves were fitted using the
LQ model. PEs were 61.0 ± 10.0% (MDA-MB-231), 35.4 ± 2.7%
(MDA-MB-468), 11.6 ± 1.1% (MDA-MB-436), 27.3 ± 1.3% (MCF-7)
and 17.0 ± 4.3% (T47D). Data represent the average surviving fraction
± SD of three independent experiments with each experiment conducted
in triplicate. (*P < 0.05 vs control)
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breast cell growth, however, slightly higher concentra-
tions were required suggesting that indolequinone deriva-
tives have different potencies in different cancer cell
types. In pancreatic cancer cell lines, the inhibition of
TrxR by indolequinones caused a shift in the redox state
and activated p38/c-Jun NH2-terminal kinase which
subsequently led to the induction apoptosis [17].
Another study reported that knockdown of TrxR1 de-
creased cell proliferation and colony growth of multiple
myeloma [34], whereas, in an animal study, TrxR-1
knockout led to embryonic lethality in mice [35].
Fig. 4 Effect of IQ9 on the expression of Trx family protein expression. Representative Western blots of three independent experiments. β-actin was
used as the loading control (42 kDa). The signals of Trx and Txnip were normalised by β-actin signals. (*P < 0.05 vs control)
Table 3 The effect of IQ9 on LQ
parameters after 4- and 48-h drug
treatment







4 h MDA-MB-231 Control 0.28±0.01 0.61±0.08 0.06±0.01 10.28±2.84 1.20
IQ9 0.21±0.02* 0.70±0.17 0.06±0.01 11.67±3.63
MDA-MB-468 Control 0.36±0.05 0.61±0.04 0.02±0.00 30.03±3.62 1.30
IQ9 0.19±0.01* 0.85±0.08* 0.01±0.00 85.00±8.18
MDA-MB-436 Control 0.19±0.04 0.74±0.11 0.03±0.01 24.66±12.93 1.43
IQ9 0.07±0.01* 1.33±0.06* 0.02±0.00 66.53±2.89
T47D Control 0.47±0.03 0.41±0.10 0.04±0.01 10.25±5.01 1.00
IQ9 0.45±0.02 0.47±0.04 0.03±0.00 15.66±1.17
MCF-7 Control 0.38±0.10 0.49±0.06 0.06±0.01 8.16±1.50 1.08
IQ9 0.24±0.10 0.58±0.18 0.08±0.02 7.25±3.19
48 h MDA-MB-231 Control 0.24±0.04 0.71±0.10 0.05±0.01 13.31±5.84 1.07
IQ9 0.22±0.08 0.85±0.04 0.03±0.01 25.60±4.62
T47D Control 0.33±0.03 0.48±0.13 0.05±0.01 9.59±5.59 1.00
IQ9 0.31±0.04 0.40±0.12 0.05±0.02 7.27±5.53
Abbreviations: SF2 surviving fraction at 2 Gy. α represents the initial slope and β refers to the terminal slope of
the dose-response curve. α/β ratio is the dose where the linear and quadratic components are equal. SER is the
sensitiser enhancement ratio. (*P < 0.05 vs control). Data represent the average ± SD of three independent exper-
iments with each experiment conducted in triplicates
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Preclinical studies have shown that modulation of redox
homeostasis could alter the response of cancer cells to low
LET radiations often used in conventional radiotherapy [7,
36]. Current data demonstrate IQ9 treatment for 4 h followed
by irradiation resulted in significant increases in radiosensitiv-
ity of TNBC cells with SER values ranging from 1.20 to 1.43
but with little effect in luminal breast cancer models. Such
data suggest that IQ9 regulates breast cancer radiosensitivity
in a phenotypic-specific manner. In terms of radiobiological
parameters, treatment with IQ9 significantly increased α in
MDA-MB-436 and MDA-MB-468 by a factor of 1.8 and
1.4 , respect ively, which represents a benefic ia l
radiosensitisation, and the α/β ratio becomes so large that
the resulting survival curves are effectively a straight line
(rather like the case when high LET radiations are used).
This suggests that there may be no fractionation benefit in
these cell lines when the drug is added, and the combined cell
kill and enhanced radiosensitivity would additionally allow
the total dose to be reduced. When breast cancer cells were
treated with IQ9 for 48 h followed by irradiation no
radiosensitisation was observed in either TNBC or luminal
phenotypes - the lack of TrxR enzyme inhibition at 48-h IQ9
treatment may explain such lack of radiosensitisation at this
time point. Inhibition of TrxR activity has been shown to
increase response to radiotherapy [36, 37]. The level of
radiosensitisation of IQ9 observed in this study is comparable
with curcumin. In previous preclinical studies, curcumin has
been shown to improve radiosensitivity of renal (SER 1.42)
[38] and breast (SER 1.38–1.78) cancer lines [39].
MDA-MB-436, a BRCA1 deficient cell line, was shown to
be the most sensitive to IQ9 treatment with the lowest IC50
value in cytotoxicity and enzyme activity assays, and greatest
SER than those cell lines with functional BRCA1 status.
BRCA1 is a protein that plays a major role in DNA repair
[40]. Earlier studies have shown that cells carrying a mutation
of BRCA genes display lower clonogenic survival [41, 42]. In
this study, T47D cells were the most resistant to IQ9, radiation
alone, and IQ9-radiation combination treatments. The high
level of endogenous Trx in T47D cells may be one of the
factors contributing to the resistance of this cell line in both
cytotoxic and radiation combination experiments. High ex-
pression of Trx is associated with resistance to several chemo-
therapeutic agents such as docetaxel [43].
Treatment with IQ9 significantly increased the expres-
sion of Trx in MDA-MB-231 cells, but this was not ob-
served in other cell lines suggesting that IQ9 may regulate
Trx expression, although the effect may be cell type-specif-
ic. IQ9 upregulated the expression of TrxR in luminal but
not in TNBC cells suggesting that luminal cells may in-
crease TrxR expression to compensate the inhibition in
TrxR activity. Inhibition of TrxR, and ultimately the entire
Trx system, contributes to the induction of oxidative stress
[44]. Treatment with IQ9 may induce oxidative stress
conditions inside the cells, activating signalling pathways
that regulate antioxidant enzyme expression. The observed
changes in expression of the enzymes may indicate the ex-
pression required in individual cell lines to attempt to main-
tain an intracellular redox balance. In glioma cells, treat-
ment with novel TrxR1 inhibitors increased mRNA expres-
sion of Trx and TrxR1 in response to high ROS levels [45].
In addition, an increase in the TrxR expression may be one
of the reasons why luminal cells did not show as much
increased radiosensitivity following IQ9 treatment. A re-
cent study demonstrated that radiosensitivity of glioma cells
was decreased by TrxR1 overexpression [46].
The present data demonstrate that the efficacy of IQ9 de-
creases following longer exposure. IQ9 is an analogue of
ES936, an NQO1 inhibitor developed from EO9 which has
been shown to be a potent anticancer agent against pancreatic
cancer cells [47]. Based on the biostability study of ES936, the
ability to inhibit NAD(P)H: quinone oxidoreductase 1 activity
was only observed between 2 to 4 h of incubation in complete
media [48]. On the other hand, EO9, a synthetic derivative of
mitomycin C has been shown to only penetrate a few microns
from blood vessels and has rapid clearance [49]. Taken to-
gether, these indicate that indolequinone compounds are only
active under short-term exposure. When a drug has a short
half-life, frequent dosing may be required to maintain the de-
sired effects; however, this may pose a challenge to achieve
optimal efficacy and minimised toxicity [50]. Clinically many
chemotherapy drugs, such as 5-fluorouracil (5-FU), have rel-
atively short half-lives (less than 20 min for 5-FU) and are
administered as continuous intravenous infusions [51].
In summary, IQ9 is a novel anticancer agent with the ability
to inhibit breast cancer cell growth and survival at low micro-
molar concentrations. It preferentially sensitises TNBC to i-
onising radiation if irradiated shortly after drug exposure. The
increase in the radiosensitivity by IQ9 may be due to the
inhibition of TrxR activity, suggesting that modulating the
Trx system may alter radioresponse. Additional work exam-
ining radiation fractionation, altered dosing regimens, and in-
corporating in vivo animal models is warranted to determine
the safe dose and to assess for any potential toxicities.
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